BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gosmanov AR, Wan J. Low positive predictive value of hemoglobin A1c for diagnosis of prediabetes in clinical practice. Am J Med Sci. 2014;348:191-194. [PMID: 24556928 DOI: 10.1097/maj.0000000000000223] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Ipsen EØ, Madsen KS, Chi Y, Pedersen-Bjergaard U, Richter B, Metzendorf MI, Hemmingsen B. Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev 2020;11:CD013516. [PMID: 33210751 DOI: 10.1002/14651858.CD013516.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
2 Oh MR, Jung SJ, Bae EJ, Park BH, Chae SW. Clinical Characteristics and Associated Risk Factors of Prediabetes in the Southwestern Region of Korea from 2010-2019. J Clin Med 2020;9:E1114. [PMID: 32295016 DOI: 10.3390/jcm9041114] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
3 Ørskov Ipsen E, Madsen KS, Pedersen-bjergaard U, Richter B, Metzendorf M, Hemmingsen B. Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2020. [DOI: 10.1002/14651858.cd013516] [Reference Citation Analysis]
4 Madsen KS, Chi Y, Metzendorf MI, Richter B, Hemmingsen B. Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev 2019;12:CD008558. [PMID: 31794067 DOI: 10.1002/14651858.CD008558.pub2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
5 Rathi N, Whelton PK, Chertow GM, Cushman WC, Cheung AK, Wei G, Boucher R, Kimmel PL, Bress AP, Kramer HJ, Al-Marji C, Greene T, Beddhu S. Influence of Prediabetes on the Effects of Intensive Systolic Blood Pressure Control on Kidney Events. Am J Hypertens 2019;32:1170-7. [PMID: 31257407 DOI: 10.1093/ajh/hpz105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
6 Moelands SV, Lucassen PL, Akkermans RP, De Grauw WJ, Van de Laar FA. Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus. Cochrane Database Syst Rev 2018;12:CD005061. [PMID: 30592787 DOI: 10.1002/14651858.CD005061.pub3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
7 Ahn HY, Kim M, Seo CR, Yoo HJ, Lee SH, Lee JH. The effects of Jerusalem artichoke and fermented soybean powder mixture supplementation on blood glucose and oxidative stress in subjects with prediabetes or newly diagnosed type 2 diabetes. Nutr Diabetes 2018;8:42. [PMID: 30026514 DOI: 10.1038/s41387-018-0052-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
8 Spiller S, Li Y, Blüher M, Welch L, Hoffmann R. Diagnostic Accuracy of Protein Glycation Sites in Long-Term Controlled Patients with Type 2 Diabetes Mellitus and Their Prognostic Potential for Early Diagnosis. Pharmaceuticals (Basel) 2018;11:E38. [PMID: 29710851 DOI: 10.3390/ph11020038] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
9 Hemmingsen B, Gimenez-Perez G, Mauricio D, Roqué I Figuls M, Metzendorf MI, Richter B. Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus. Cochrane Database Syst Rev 2017;12:CD003054. [PMID: 29205264 DOI: 10.1002/14651858.CD003054.pub4] [Cited by in Crossref: 54] [Cited by in F6Publishing: 87] [Article Influence: 10.8] [Reference Citation Analysis]
10 Richter B, Hemmingsen B, Metzendorf M, Takwoingi Y; Cochrane Metabolic and Endocrine Disorders Group. Intermediate hyperglycaemia as a predictor for the development of type 2 diabetes: prognostic factor exemplar review. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd012661] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
11 Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev 2017;5:CD012204. [PMID: 28489279 DOI: 10.1002/14651858.CD012204.pub2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
12 Onat A, Karadeniz Y, Can G, Karakoyun S, Özpamuk-Karadeniz F, Kaya A, Yüksel H. Fasting glycemia and glycated hemoglobin categories: Relationship to serum lipoprotein(a) level and disparity in 2 geographic regional groups of Turkey. Anatol J Cardiol 2017;17:191-9. [PMID: 27849191 DOI: 10.14744/AnatolJCardiol.2016.7190] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev 2016;10:CD012151. [PMID: 27749986 DOI: 10.1002/14651858.CD012151.pub2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
14 Hemmingsen B, Krogh J, Metzendorf MI, Richter B. Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev 2016;4:CD012106. [PMID: 27101360 DOI: 10.1002/14651858.CD012106.pub2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
15 Hemmingsen B, Sonne DP, Metzendorf M, Richter B. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2016. [DOI: 10.1002/14651858.cd012151] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
16 Hemmingsen B, Krogh J, Metzendorf M, Richter B. Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2016. [DOI: 10.1002/14651858.cd012106] [Reference Citation Analysis]
17 Bansal N. Prediabetes diagnosis and treatment: A review. World J Diabetes 2015; 6(2): 296-303 [PMID: 25789110 DOI: 10.4239/wjd.v6.i2.296] [Cited by in CrossRef: 243] [Cited by in F6Publishing: 257] [Article Influence: 34.7] [Reference Citation Analysis]
18 Juarez DT, Demaris KM, Goo R, Mnatzaganian CL, Wong Smith H. Significance of HbA1c and its measurement in the diagnosis of diabetes mellitus: US experience. Diabetes Metab Syndr Obes 2014;7:487-94. [PMID: 25349480 DOI: 10.2147/DMSO.S39092] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]